ADVFN - Advanced Financial Network.
Free Real-time News Alerts: Tell us which stocks you're watching and we'll send you the latest news as it is released direct to your e-mail.
News alerts
HOME» AMEX » H » HEB Stock Price

Hemispherx Stock Price

 Hemispherx Biopharma, Stock Price
HEB Stock Price
 Hemispherx Biopharma, Stock Chart
HEB Stock Chart
 Hemispherx Biopharma, Stock News
HEB Stock News
 Hemispherx Biopharma, Company Information
HEB Company Information
 Hemispherx Biopharma, Stock Trades
HEB Stock Trades
Hemispherx (HEB)
URL : Hemispherx Biopharma
0.28 HEB -0.02
-0.02 (-5.35%)

Company Description : Hemispherx Biopharma, Inc. is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Hemispherx Stock
Share Price0.28
Bid Price-
Ask Price-
% Change-5.35%
Last Change Time16:19:22
Yesterday's Close0.30
Hemispherx Stock Chart
October 2013 to October 2014
Hemispherx Biopharma, Historical Stock Chart October 2013 to October 2014
More HEB Stock Trades »Hemispherx : Stock Trades Table
TimePriceSizeTypeBid PriceOffer PriceNumberBuy / Sell
18:11:300.291form t0.290.291,223U
17:47:040.291form t0.290.291,222U
17:45:580.291form t0.290.291,221U
17:40:340.291form t0.290.291,220U
17:37:290.299,000form t0.290.291,219U
17:35:260.291form t0.290.291,218U
17:34:400.291form t0.290.291,217U
17:21:110.291form t0.290.291,216U
16:19:220.29100form t0.290.291,215U
16:19:220.29100form t0.290.291,214U
Live Intraday Hemispherx Stock Quote
Sunday, 26 October 2014
Hemispherx Biopharma, Intraday Stock Chart Sunday, 26 October 2014

Hemispherx Biopharma and other American Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations